CLINICAL TRIALS PROFILE FOR TYBOST
✉ Email this page to a colleague
All Clinical Trials for Tybost
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT02503462 ↗ | Effect of Cobicistat Versus Ritonavir Boosting on the Brain Permeation of Darunavir in HIV-infected Individuals | Terminated | University Hospital, Basel, Switzerland | Phase 4 | 2015-07-01 | The purpose of this study is to assess whether a boosting by cobicistat results in similar concentrations of darunavir in the brain compared to a boosting by ritonavir. |
| NCT02565888 ↗ | A Drug-drug Interaction Study Between Daclatasvir and Atazanavir/Ritonavir or Atazanavir/Cobicistat | Completed | Radboud University | Phase 1 | 2015-11-01 | This study aims to provide the evidence that 150mg of cobicistat will have the same effect on the pharmacokinetics of daclatasvir 30mg QD as 100mg of ritonavir, when given together with atazanavir 300mg. |
| NCT03858491 ↗ | Pharmacokinetic Boosting of Osimertinib | Recruiting | The Netherlands Cancer Institute | Early Phase 1 | 2020-11-01 | The main objective of this study is to evaluate if systemic exposure of osimertinib (i.e. AUC) is increased when osimertinib is co-administered with cobicistat in patients with relatively low plasma trough concentration while receiving the standard osimertinib dose. |
| NCT03858491 ↗ | Pharmacokinetic Boosting of Osimertinib | Recruiting | ZonMw: The Netherlands Organisation for Health Research and Development | Early Phase 1 | 2020-11-01 | The main objective of this study is to evaluate if systemic exposure of osimertinib (i.e. AUC) is increased when osimertinib is co-administered with cobicistat in patients with relatively low plasma trough concentration while receiving the standard osimertinib dose. |
| NCT03858491 ↗ | Pharmacokinetic Boosting of Osimertinib | Recruiting | Academisch Ziekenhuis Maastricht | Early Phase 1 | 2020-11-01 | The main objective of this study is to evaluate if systemic exposure of osimertinib (i.e. AUC) is increased when osimertinib is co-administered with cobicistat in patients with relatively low plasma trough concentration while receiving the standard osimertinib dose. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Tybost
Condition Name
Clinical Trial Locations for Tybost
Trials by Country
Clinical Trial Progress for Tybost
Clinical Trial Phase
Clinical Trial Sponsors for Tybost
Sponsor Name
